<DOC>
	<DOCNO>NCT01902316</DOCNO>
	<brief_summary>Although diabetes control since insulin become available , still consider incurable pose serious threat human health . Reports suggest hyperglycemic condition patient diabetes mellitus may greatly alleviate even reverse could control early stage diabetes . Thus , early detection diagnosis diabetes prediabetes become increasingly important treatment prevention diabetes . Diabetes mellitus currently diagnose recurrent persistent hyperglycemia . In effort identify novel biomarkers diabetes , research show neither plasma glucose glycated hemoglobin ( HbA1c ) level unable use early detection diabetes . In work , investigator find 8 biomarker candidate develop standard-free , label-free MS-based proteomics method base standard protein ( human serum albumin , high abundance protein human plasma ) model vitro . Then , investigator want verify biomarker candidate clinical plasma sample see significant quantitative difference normal people diabetes patient .</brief_summary>
	<brief_title>Clinical Verification Peptide Biomarkers Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The procedure clinical study : 1. get plasma sample hospital ; 2. digestion plasma protein-mixture trypsin ; 3. run mass spectrometry monitor amount target HSA-peptides .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 Diabetes Mellitus case ; Impaired Glucose Tolerance case ; Normal Glucose Tolerance case Type 1 Diabetes Mellitus case ; Gestational Diabetes Mellitus case ; Hepatitis patient</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>peptide biomarker</keyword>
	<keyword>early diagnosis</keyword>
	<keyword>label free</keyword>
</DOC>